Established in 1992, bluebird bio develops gene therapies used to treat cancer and severe genetic diseases. The company was founded by Philippe Leboulch, the co-chair of the Scientific Advisory Board, a community of medical and scientific experts, and the leader of the LentiGlobin Project, which targets sickle cell disease. Headquartered in Cambridge, Massachusetts, bluebird bio has additional U.S. and international operations in Seattle, Washington, and Switzerland.

bluebird bio manages integrated product platforms focused on cancer immunotherapy and gene editing and therapy. It's used to provide broad therapeutic potential and treatment options, and ideally, cures, for a wide range of serious diseases. The company's objective is to develop advanced medical products and bring them to market as one-time treatment options for patients suffering from cancer and other severe genetic and rare diseases. bluebird bio's mission is propelled by a collective determination to provide patients with hope for a better life despite facing otherwise limited treatment alternatives. Its development is led by the Boston's Children's Hospital and other collaborators, such as Celegene. Some of the treatments bluebird bio has worked on address multiple myeloma, cerebral adrenoleukodystrophy, and Cooley's anemia, a blood disorder.

As an employer, bluebird bio hires applicants who can fortify its position at the forefront of the gene therapy revolution. A product-oriented, patient- and purpose-driven organization, it is comprised of a "diverse flock of bluebirds" who share a singular focus: change the lives of patients and support one another throughout the journey. Team members maintain a "never-give-up, little-but-mighty attitude" exhibited by the company's namesake, the Eastern Bluebird. Flexible bluebird bio jobs offered in the past include freelance positions, some of which feature long-term contracts, and full-time employment with telecommuting options.

Established in 1992, bluebird bio develops gene therapies used to treat cancer and severe genetic diseases. The company was founded by Philippe Leboulch, the co-chair of the Scientific Advisory Board, a community of medical and scientific experts, and the leader of the LentiGlobin Project, which targets sickle cell disease. Headquartered in Cambridge, Massachusetts, bluebird bio has additional U.S. and international operations in Seattle, Washington, and Switzerland.

bluebird bio manages integrated product platforms focused on cancer immunotherapy and gene editing and therapy. It's used to provide broad therapeutic potential and treatment options, and ideally, cures, for a wide range of serious diseases. The company's objective is to develop advanced medical products and bring them to market as one-time treatment options for patients suffering from cancer and other severe genetic and rare diseases. bluebird bio's mission is propelled by a collective determination to provide patients with hope for a better life despite facing otherwise limited treatment alternatives. Its development is led by the Boston's Children's Hospital and other collaborators, such as Celegene. Some of the treatments bluebird bio has worked on address multiple myeloma, cerebral adrenoleukodystrophy, and Cooley's anemia, a blood disorder.

As an employer, bluebird bio hires applicants who can fortify its position at the forefront of the gene therapy revolution. A product-oriented, patient- and purpose-driven organization, it is comprised of a "diverse flock of bluebirds" who share a singular focus: change the lives of patients and support one another throughout the journey. Team members maintain a "never-give-up, little-but-mighty attitude" exhibited by the company's namesake, the Eastern Bluebird. Flexible bluebird bio jobs offered in the past include freelance positions, some of which feature long-term contracts, and full-time employment with telecommuting options.